EUVIMEDEUVIMED entdecken
Crossref

Clinical Application and Research Progress of Novel Anti-Obesity Medications

博 商

Pharmacy Information · 2026 · 15 (04) · 402-411

DOI: 10.12677/pi.2026.154043 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacy Information, 2026. Verfasst von 博 商. Die Arbeit nennt 53 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

肥胖已成为全球性公共卫生问题,易诱发糖尿病、心脑血管疾病等多种并发症,严重威胁百姓身体健康。单纯依靠饮食管控与运动锻炼进行减重,患者长期依从性较差,整体干预效果有限,减重药物现已成为肥胖综合诊疗中重要的辅助治疗手段。当前临床常用减重药物主要分为脂肪酶抑制剂、GLP-1受体激动剂及中枢复方制剂三大类,主流用药包含奥利司他、利拉鲁肽、司美格鲁肽、贝那鲁肽、奥氟格列隆、替尔泊肽、玛仕度肽、瑞他鲁肽、纳曲酮/安非他酮、芬特明/托吡酯等。本文归纳各类减重药物的作用机理、临床疗效及安全特性,分析现阶段药物应用存在的实际问题,探讨减重药物研发方向与临床应用发展趋势,为临床科学选用减重药物、规范开展肥胖药物治疗提供参考依据。Obesity has evolved into a global public health crisis, as it predisposes individuals to multiple complications such as diabetes mellitus and cardiovascular and cerebrovascular diseases, thereby posing a severe threat to human health. Weight management relying solely on dietary restriction and physical exercise often suffers from poor long-term patient adherence and limited overall intervention efficacy. Consequently, anti-obesity medications have become an essential adjunctive therapy in the comprehensive diagnosis and treatment of obesity. Clinically prevalent anti-obesity drugs are primarily categorized into three classes: lipase inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and central nervous system combination preparations. The mainstream agents include orlistat, liraglutide, semaglutide, benaglutide, orforglipron, tirzepatide, mazdutide, retatrutide, naltrexone/bupropion, and phentermine/topiramate. This article systematically summarizes the mechanisms of action, clinical efficacy and safety profiles of each class of anti-obesity drugs, analyzes the practical challenges associated with their current clinical application, and discusses the research priorities and developmental trends of anti-obesity drugs. It aims to provide evidence-based references for rational medication selection and standardized pharmacotherapy for obesity in clinical practice.

Zitieren

APA

商, 博. (2026). Clinical Application and Research Progress of Novel Anti-Obesity Medications. Pharmacy Information, 15(04), 402-411. https://doi.org/10.12677/pi.2026.154043

Vancouver

商 博. Clinical Application and Research Progress of Novel Anti-Obesity Medications. Pharmacy Information. 2026;15(04):402-411. doi:10.12677/pi.2026.154043

BibTeX
@article{2026,
  author = {商, 博},
  title = {Clinical Application and Research Progress of Novel Anti-Obesity Medications},
  journal = {Pharmacy Information},
  year = {2026},
  volume = {15},
  number = {04},
  pages = {402--411},
  doi = {10.12677/pi.2026.154043}
}
Kostenlos starten →